Sage Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sage Therapeutics's estimated annual revenue is currently $97.7M per year.
- Sage Therapeutics received $575.0M in venture funding in February 2018.
- Sage Therapeutics's estimated revenue per employee is $127,148
- Sage Therapeutics's total funding is $1.1B.
- Sage Therapeutics has 768 Employees.
- Sage Therapeutics grew their employee count by 4% last year.
Sage Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Sage Therapeutics?
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Sage Therapeutics News
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health,...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Recommendation of Hold from Brokerages. Posted by admin on Apr 18th, 2022.
Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-label SHORELINE Study. This clinical study was designed to naturalistically fol ...
On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Sage Therapeutics Funding
|2013-10-17||$20.0M||B||ARCH Venture Partners||Article|
|2015-04-15||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-04-22||$138.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-11-15||$345.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2018-02-09||$575.0M||Undisclosed||J.P. Morgan Securities LLC||Article|